» Articles » PMID: 23437058

Effect of Natural and ARV-induced Viral Suppression and Viral Breakthrough on Anti-HIV Antibody Proportion and Avidity in Patients with HIV-1 Subtype B Infection

Overview
Journal PLoS One
Date 2013 Feb 26
PMID 23437058
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Viral suppression and viral breakthrough impact the humoral immune response to HIV infection. We evaluated the impact of viral suppression and viral breakthrough on results obtained with two cross-sectional HIV incidence assays.

Methods: All samples were collected from adults in the US who were HIV infected for >2 years. Samples were tested with the BED capture enzyme immunoassay (BED-CEIA) which measures the proportion of IgG that is HIV-specific, and with an antibody avidity assay based on the Genetic Systems 1/2+ O ELISA. We tested 281 samples: (1) 30 samples from 18 patients with natural control of HIV-1 infection known as elite controllers or suppressors (2) 72 samples from 18 adults on antiretroviral therapy (ART), with 1 sample before and 2-6 samples after ART initiation, and (3) 179 samples from 20 virally-suppressed adults who had evidence of viral breakthrough receiving ART (>400 copies/ml HIV RNA) and with subsequent viral suppression.

Results: For elite suppressors, 10/18 had BED-CEIA values <0.8 normalized optical density units (OD-n) and these values did not change significantly over time. For patients receiving ART, 14/18 had BED-CEIA values that decreased over time, with a median decrease of 0.42 OD-n (range 0.10 to 0.63)/time point receiving ART. Three patterns of BED-CEIA values were observed during viral breakthrough: (1) values that increased then returned to pre-breakthrough values when viral suppression was re-established, (2) values that increased after viral breakthrough, and (3) values that did not change with viral breakthrough.

Conclusions: Viral suppression and viral breakthrough were associated with changes in BED-CEIA values, reflecting changes in the proportion of HIV-specific IgG. These changes can result in misclassification of patients with long-term HIV infection as recently infected using the BED-CEIA, thereby influencing a falsely high value for cross-sectional incidence estimates.

Citing Articles

Identification of antibody targets associated with lower HIV viral load and viremic control.

Grant-McAuley W, Morgenlander W, Ruczinski I, Kammers K, Laeyendecker O, Hudelson S PLoS One. 2024; 19(9):e0305976.

PMID: 39288118 PMC: 11407625. DOI: 10.1371/journal.pone.0305976.


Evaluation of multi-assay algorithms for cross-sectional HIV incidence estimation in settings with universal antiretroviral treatment.

Grant-McAuley W, Laeyendecker O, Monaco D, Chen A, Hudelson S, Klock E BMC Infect Dis. 2022; 22(1):838.

PMID: 36368950 PMC: 9652879. DOI: 10.1186/s12879-022-07850-0.


Recent HIV Infection: Diagnosis and Public Health Implications.

Nikolopoulos G, Tsantes A Diagnostics (Basel). 2022; 12(11).

PMID: 36359500 PMC: 9689622. DOI: 10.3390/diagnostics12112657.


Evaluation of multi-assay algorithms for identifying individuals with recent HIV infection: HPTN 071 (PopART).

Grant-McAuley W, Klock E, Laeyendecker O, Piwowar-Manning E, Wilson E, Clarke W PLoS One. 2021; 16(12):e0258644.

PMID: 34919554 PMC: 8682874. DOI: 10.1371/journal.pone.0258644.


Validation of population-level HIV-1 incidence estimation by cross-sectional incidence assays in the HPTN 071 (PopART) trial.

Klock E, Wilson E, Fernandez R, Piwowar-Manning E, Moore A, Kosloff B J Int AIDS Soc. 2021; 24(12):e25830.

PMID: 34897992 PMC: 8666582. DOI: 10.1002/jia2.25830.


References
1.
Moore R . Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 17 Suppl 1:S38-41. DOI: 10.1097/00042560-199801001-00011. View

2.
Zhang C, Denti P, van der Walt J, Ren Y, Smith P, Karlsson M . Population pharmacokinetic model for adherence evaluation using lamivudine concentration monitoring. Ther Drug Monit. 2012; 34(4):481-4. DOI: 10.1097/FTD.0b013e31825c6067. View

3.
Laeyendecker O, Brookmeyer R, Oliver A, Mullis C, Eaton K, Mueller A . Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay. AIDS Res Hum Retroviruses. 2011; 28(8):816-22. PMC: 3399553. DOI: 10.1089/aid.2011.0258. View

4.
Bailey J, Lassen K, Yang H, Quinn T, Ray S, Blankson J . Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol. 2006; 80(10):4758-70. PMC: 1472047. DOI: 10.1128/JVI.80.10.4758-4770.2006. View

5.
Janssen R, Satten G, Stramer S, RAWAL B, OBrien T, Weiblen B . New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998; 280(1):42-8. DOI: 10.1001/jama.280.1.42. View